Obayashi to Acquire Multiplex in $526M Expansion Deal 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Trump Says Anthropic No Longer Seen as National Security Threat 
SAN RAMON, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at NobleCon12 - Noble Financial Capital Markets’ Twelfth Annual Investor Conference. The presentation will take place on Monday, January 18, 2015 at 2:30 p.m. ET in Sandpiper Bay, Florida.
The presentation will be webcast and available on the Investors section of the Company's website at http://investors.galenabiopharma.com/events.cfm.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancer and in a Phase 1b given sequentially with GALE-302. For more information, visit www.galenabiopharma.com.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact:
Remy Bernarda
SVP, Investor Relations & Corporate Communications
(925) 498-7709
[email protected]
